HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50

Seaport Therapeutics

Seaport Therapeutics

SPTX

0.00

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Buy rating and announces Price Target of $50.